Testing an updated quality-of-life questionnaire for people with ovarian cancer
Pre-tests the EORTC QLQ-OV39 questionnaire in adults with ovarian cancer.
Plain-language title generated from the registry record
Registry title: Updating the EORTC Quality-of-Life Questionnaire for Ovarian Cancer (QLQ-OV38)
Key facts
- Where
- Wuppertal, GermanySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women over 18 with early or advanced ovarian cancer who can fill in questionnaires about their quality of life.
- Age
- Over 18 years
- Sex
- Women only
- Disease stage
- Early (FIGO I-II) or advanced (FIGO II-IV) ovarian cancer
Main reasons for not taking part
- Cognitive impairment
- Cannot or will not complete the questionnaires
- Cannot understand or speak the language of the questionnaire
Read by machine on 13 November 2026.
Where in Germany
- Helios University Clinic Wuppertal, University Witten/HerdeckeWuppertal, GermanyContact: Vesna Bjelic-Radisic, ProfNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Helios University Hospital Wuppertal
- Trial code
- NCT07465133
- Record updated
- 18 September 2026
- Original description
The goal of this observational study is to pre-test the EORTC QLQ-OV39 to identify and resolve potential problems in its administration and to identify missing/redundant items. A preliminary evaluation of the measurement properties of the module will be carried out.Read full original descriptionShow less
The Update of the EORTC QLQ-Ovarial Cancer Module (EORTC-QLQ-OV28) - OV39 Phase III
The goal of this observational study is to pre-test the EORTC QLQ-OV39 to identify and resolve potential problems in its administration and to identify missing/redundant items. A preliminary evaluation of the measurement properties of the module will be carried out.
The study includes patients with evidence of localized (FIGO I-II) or advanced ovarian cancer (FIGO II-IV) above the age of 18 years.
The main aims are:
1. To conduct Phase 3a and 3b pre-testing of the preliminary EORTC-QLQ-OV39 Questionnaire to identify and resolve potential problems in its administration and to identify missing/redundant items according to the updated EORTC QLG Guidelines for Module Development, 5th Edition 2021.(16) 2. a preliminary assessment of the psychometric properties of the module
Participants will [describe the main tasks participants will be asked to, complete the OV39, C30 and debriefing interviews, as well as questions about their demographics and clinical data.
Inclusion: Evidence of localized (FIGO I-II) or advanced ovarian cancer (FIGO II-IV); Must be able and willing to complete the questionnaires; Must be able to understand and speak the language in which the patient will complete the questionnaire; Age > 18 years.
Exclusion: cognitive impairment.